You are here: Industry Insights > Market News > Inspire files for $86.25M IPO

Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!

Note: You can unsubscribe from the alerts at any time.

Advertising

New Products

Gelatin, Soft Capsule Gelatin, Hard Capsule Gelatin, Pharmaceutical Gelatin-Foodmate

Neohesperidin

Advantame

Cleanroom Bench Horizontal Laminar Flow Hood Airflow Clean Bench

Pharma and Food Grade, USP/FCC Neotame Sweetener E961

Trilobatin

Inspire files for $86.25M IPO

biospectrumasiaApril 10, 2018

Tag: IPO , Inspire

Favorites

The Maple Grove-based company, Inspire Medical Systems, which sells its proprietary Inspire therapy for sleep apnea, has filed for an initial public offering seeking up to $86.25M.

BofA Merrill Lynch and Goldman Sachs are the joint bookrunners on the deal. For the year ended Dec. 31, 2017, the company posted $28.6M in revenue, with $22.55M of that going through as gross profit.

Register as Visitor to CPhI China 2018!

Previous:Protalex Initiates Fourth Cohort Dosing of Phase 1/2 Study of PRTX-100 in Immune Thrombocytopenia

Next:Thermo Fisher collaborates with Ortho Clinical Diagnostics

Everest Medicines Announces Acceptance of the New Drug Application for VELSIPITY

Everest Medicines LimitedDecember 20, 2024

Everest Medicines announced NMPA acceptance of NDA for VELSIPITY(R) (etrasimod) to treat moderately to severely active UC.

Manulife Hong Kong Partners with New Frontier Group to Enhance Cross-Border Healthcare Services

PRNewswireDecember 12, 2024

Menarini Group and MEDSIR Present the Phase III Study ADELA: A New Therapeutic Strategy for Advanced Breast Cancer

PRNewswireDecember 12, 2024

Inspire files for $86.25M IPO | Pharmasources.com

Core8 Group and MedArmor to Pioneer Vietnam's First AI x ESG Hospital

PRNewswireDecember 12, 2024

Core8 Group, an Australian leader in high-tech and biotech innovation, has unveiled plans to develop Vietnam's first AI x ESG Hospital, marking a significant milestone in healthcare transformation.

Inspire files for $86.25M IPO

Related News

Everest Medicines Announces Acceptance of the New Drug Application for VELSIPITY

Manulife Hong Kong Partners with New Frontier Group to Enhance Cross-Border Healthcare Services

Menarini Group and MEDSIR Present the Phase III Study ADELA: A New Therapeutic Strategy for Advanced Breast Cancer

Core8 Group and MedArmor to Pioneer Vietnam's First AI x ESG Hospital

You may like
More>>

Inspire files for $86.25M IPO

Related News

Everest Medicines Announces Acceptance of the New Drug Application for VELSIPITY

Manulife Hong Kong Partners with New Frontier Group to Enhance Cross-Border Healthcare Services

Menarini Group and MEDSIR Present the Phase III Study ADELA: A New Therapeutic Strategy for Advanced Breast Cancer

Core8 Group and MedArmor to Pioneer Vietnam's First AI x ESG Hospital

You may likeMore>>

You may like
More>>